IMC-A12 is a new cancer treatment that has not yet been approved by the U.S. Food and Drug Administration
It is an antibody that is designed to block the effects of a protein called Type I Insulin-Like Growth Factor (IGF-1R). IMC-A12 blocks the receptors in cells that respond to IGF-1R, which are thought to play an important role in helping cancer cells to grow and divide.
Researchers are interested in determining whether IMC-A12 is an effective treatment for individuals who have mesothelioma that has not responded to standard chemotherapy.
The objective if this study it to evaluate the safety and effectiveness of IMC-A12 treatment in individuals with mesothelioma who have previously had chemotherapy.
Individuals at least 18 years of age who have been diagnosed with mesothelioma that has not responded to chemotherapy are eligible.
Eligible participants will be screened with a full physical examination and medical history, blood and urine samples, and imaging studies.
Participants will receive IMC-A12 once every 3 weeks (21-day cycle), and will be evaluated before the start of each new cycle with blood tests and imaging studies if needed.
Treatment cycles will continue for as long as needed, unless severe side effects develop or the disease progresses.
This study is currently recruiting participants. This study has been verified by National Institutes of Health Clinical Center (CC), June 2010
It is an antibody that is designed to block the effects of a protein called Type I Insulin-Like Growth Factor (IGF-1R). IMC-A12 blocks the receptors in cells that respond to IGF-1R, which are thought to play an important role in helping cancer cells to grow and divide.
Researchers are interested in determining whether IMC-A12 is an effective treatment for individuals who have mesothelioma that has not responded to standard chemotherapy.
The objective if this study it to evaluate the safety and effectiveness of IMC-A12 treatment in individuals with mesothelioma who have previously had chemotherapy.
Individuals at least 18 years of age who have been diagnosed with mesothelioma that has not responded to chemotherapy are eligible.
Eligible participants will be screened with a full physical examination and medical history, blood and urine samples, and imaging studies.
Participants will receive IMC-A12 once every 3 weeks (21-day cycle), and will be evaluated before the start of each new cycle with blood tests and imaging studies if needed.
Treatment cycles will continue for as long as needed, unless severe side effects develop or the disease progresses.
This study is currently recruiting participants. This study has been verified by National Institutes of Health Clinical Center (CC), June 2010
No comments:
Post a Comment